NutriLeads attracts Series B funding to launch its innovative immune-enhancing ingredient, Xtramune™, and to progress its portfolio of health ingredients

NutriLeads attracts Series B funding to launch its innovative immune-enhancing ingredient, Xtramune™, and to progress its portfolio of health ingredients

Dutch Health Ingredients company, NutriLeads, announces the closing of a Series B financing round of 6.5 m€, led by ICOS Capital together with Goeie-Grutten and existing shareholders DSM Venturing, Oost NL, SHIFT Invest and Thuja.

NutriLeads, established in 2012, develops innovative natural food ingredients with clinically proven health benefits for application in dietary supplements and functional foods. Its proprietary lead ingredient, XtramuneTM, is a unique carrot-derived fibre supporting immune function and resistance to respiratory infections.
This series B funding round marks a new phase for the company. Together with global partners in the food and supplement industry, NutriLeads will be driving XtramuneTM towards commercialization in 2021. In addition, two other ingredients from its portfolio, targeting gut health and metabolic health, will be progressed to proof of concept in humans.
Ruud Albers, CEO of NutriLeads indicates: “We are very excited about this successful funding round which helps to propel NutriLeads forward. People can strengthen their health with nutrition. It is our ambition to unlock the potential of clinically proven food ingredients and this funding round supports that mission. It is great to see that all our investors are committed to this shared goal.”